Timothy J Iveson

9PUBLICATIONS
89CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 09, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

Timothy Iveson, Mark P Saunders, Caroline Kelly

|Mar 28, 2024
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.

Claire Gallois, Qian Shi, Levi D Pederson

|Mar 14, 2024
Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.

Enric Domingo, Caroline Kelly, Jennifer Hay

|Oct 28, 2022
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.

Claire Gallois, Qian Shi, Jeffrey P Meyers

|Mar 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.

John Bridgewater, Peter Fletcher, Daniel H Palmer

|Nov 09, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.

Elisa Fontana, Jeff Meyers, Alberto Sobrero

Pageof 2

Frequent Collaborators

7 joint publications

Andrea Harkin

4 joint publications

Eiji Oki

4 joint publications

Takayuki Yoshino

4 joint publications

Sara Lonardi